References
- Balan, G., Timmins, P., Greene, D. S., Marathe, P. H. (2001). In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. Journal of Pharmaceutical Sciences, 90, 1176–1185., [PUBMED], [INFOTRIEVE], [CSA]
- Carruthers, S. G., et al. (2000). Clinical Pharmacology (4th ed.). Beijing: McGraw-Hill, 529–551.
- Gan, Y., Pan, W., Wei, M., & Zhang, R. (2002). Cyclodextrin complex osmotic tablet for GZ delivery. Drug Development and Industrial Pharmacy, 28, 1015–1021., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Katzung, B. G. (2001). Basic and Clinical Pharmacology (8th ed.). Beijing: McGraw-Hill, 711–734.
- Matharu, et al. (2003). Pharmaceutical Composition. US Patent 20030021841. 2003-01-30.
- Scheen, A. J. (1996). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 30, 359–371., [PUBMED], [INFOTRIEVE], [CSA]
- Schug, B. S., Brendel, E., Wolf, D., Wonnemann, M., Wargenau, M., Blume, H. H. (2002). Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. European Journal of Pharmaceutical Sciences, 15, 279–285., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- U.S. Department of Health and Human Services. (1997). Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In vivo Correlation. Rockville, MD: Center for Drug Evaluation and Research (CDER).
- Verma, & Garg. (2004). Development and evaluation of osmotically controlled oral drug delivery system of glipizide. European Journal of Pharmaceutics and Biopharmaceutics, 57, 513–525., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vidon, N., et al. (1988). Metformin in the digestive tract. Diabetes Research and Clinical Practice, 4, 223–229., [PUBMED], [INFOTRIEVE], [CSA]